Literature DB >> 16449506

Darwin and the survival of the fittest in modern interventional cardiology.

V K Bhatia, C Di Mario.   

Abstract

The diabetic patient requires a full armamentarium of proven and developing treatments in order to minimise periprocedural risk as well as improve long term outcome.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16449506      PMCID： PMC1861074          DOI： 10.1136/hrt.2005.083923

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  16 in total

1.  Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent.

Authors:  Seung-Woon Rha; Pramod K Kuchulakanti; Rajbabu Pakala; Edouard Cheneau; Jana A Fournadjiev; Ellen Pinnow; Afework Gebreeyesus; George Aggrey; Zuyue Wang; Augusto D Pichard; Lowell F Satler; Kenneth M Kent; Joseph Lindsay; Ron Waksman
Journal:  Am J Cardiol       Date:  2004-10-15       Impact factor: 2.778

2.  7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

Authors:  D I Simon; H Xu; S Ortlepp; C Rogers; N K Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-03       Impact factor: 8.311

3.  Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

Authors:  D L Bhatt; S P Marso; A M Lincoff; K E Wolski; S G Ellis; E J Topol
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

4.  Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty.

Authors:  G W Barsness; E D Peterson; E M Ohman; C L Nelson; E R DeLong; J G Reves; P K Smith; R D Anderson; R H Jones; D B Mark; R M Califf
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

5.  Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation.

Authors:  S S Srivatsa; L A Fitzpatrick; P W Tsao; T M Reilly; D R Holmes; R S Schwartz; S A Mousa
Journal:  Cardiovasc Res       Date:  1997-12       Impact factor: 10.787

6.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

Authors:  Adnan Kastrati; Julinda Mehilli; Helmut Schühlen; Josef Dirschinger; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Hildegard Bollwein; Christian Volmer; Meinrad Gawaz; Peter B Berger; Albert Schömig
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

7.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.

Authors:  B Stein; W S Weintraub; S P Gebhart; C L Cohen-Bernstein; R Grosswald; H A Liberman; J S Douglas; D C Morris; S B King
Journal:  Circulation       Date:  1995-02-15       Impact factor: 29.690

8.  Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.

Authors:  Issam Moussa; Martin B Leon; Donald S Baim; William W O'Neill; Jeffery J Popma; Maurice Buchbinder; Jay Midwall; Charles A Simonton; Emily Keim; Patrick Wang; Richard E Kuntz; Jeffrey W Moses
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

Review 9.  Platelet activation in type 2 diabetes mellitus.

Authors:  P Ferroni; S Basili; A Falco; G Davì
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824

Review 10.  Potential mechanisms promoting restenosis in diabetic patients.

Authors:  D Aronson; Z Bloomgarden; E J Rayfield
Journal:  J Am Coll Cardiol       Date:  1996-03-01       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.